GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Effects of hypothyroidism, tri-iodothyronine and glucocorticoids on growth hormone responses to growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2.
Edwards. C A CA; Dieguez. C C; Scanlon. M F MF
Key Findings
- Hypothyroid rats had a ~60% drop in GH response to GHRH and a ~60% drop to GHRP‑6 compared to normal rats.
- Two weeks of T3 treatment restored GH response to GHRH (and partially to GHRP‑6) in hypothyroid rats.
- Cortisol also improved GH response, but less than T3, and the combination of T3 + cortisol was not markedly better than T3 alone.
- Pituitary cells from hypothyroid rats showed reduced sensitivity to both GHRP‑6 and somatostatin in vitro.
Practical Outcomes
- If you plan to use GHRP‑6 for growth hormone spikes, keep your thyroid function normal; hypothyroidism will blunt its effect. In cases of low thyroid, a short course of T3 (under medical supervision) may restore responsiveness. Cortisol can help a bit, but it’s not as effective as fixing thyroid status.
Summary
In rats, low thyroid hormone levels (hypothyroidism) greatly blunt the growth hormone boost you get from GHRP‑6 and from GHRH. Giving thyroid hormone (T3) or even cortisol partly restores that boost, but only when the animals are already euthyroid does the effect stay normal. The study shows that your thyroid health directly influences how well GHRP‑6 works.
Abstract
The aim of this study was to investigate the role of thyroid hormones and glucocorticoids on GH secretion. Secretion of GH in response to GH-releasing hormone (GHRH) (5 micrograms/kg) was markedly (P less than 0.001) decreased in hypothyroid rats in vivo (peak GH responses to GHRH, 635 +/- 88 micrograms/l in euthyroid rats vs 46 +/- 15 micrograms/l in hypothyroid rats). Following treatment with tri-iodothyronine (T3; 20 micrograms/day s.c. daily for 2 weeks) or cortisol (100 micrograms/day s.c. for 2 weeks) or T3 plus cortisol, a marked (P less than 0.01) increase in GH responses to GHRH was observed in hypothyroid rats (peak GH responses, 326 +/- 29 micrograms/l after T3 vs 133 +/- 19 micrograms/l after cortisol vs 283 +/- 35 micrograms/l after cortisol plus T3). In contrast, none of these treatments modified GH responses to GHRH in euthyroid animals. Hypothyroidism was also associated with impaired GH responses to the GH secretagogue, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6). Secretion of GH in response to GHRP-6 in vivo was reduced (P less than 0.01) in hypothyroid rats (peak GH responses, 508 +/- 177 micrograms/l in euthyroid rats vs 203 +/- 15 micrograms/l in hypothyroid rats). In-vitro studies carried out using monolayer cultures of rat anterior pituitary cells derived from euthyroid and hypothyroid rats showed a marked impairment of somatotroph responsiveness to both GHRP-6 and somatostatin in cultures derived from hypothyroid rats. In summary, our data suggest that thyroid hormones and glucocorticoids influence GH secretion by modulating somatotroph responsiveness to different GH secretagogues.
Study Information
pubmed
1989
10.1677/joe.0.1210031